To assess whether the signaling and anti-apoptotic effects observed by IFNα treatment in MOLM-13 was a cell line-specific effect, we treated 12 AML patient and five healthy donor PBMC samples using the same therapy combination (48 h). The gene discussed is IFNA2; the disease is acute myeloid leukemia.